0000000001021114

AUTHOR

G. Fabbrini

showing 2 related works from this author

A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial

2021

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbi…

Research ReportMale0301 basic medicineBenzylaminesParkinson's diseaseOutcome AssessmentParkinson's diseaseComorbidityDiseaseReal-life evaluationchemistry.chemical_compound0302 clinical medicineOutcome Assessment Health Care80 and overMAO-B inhibitorAged 80 and overSafinamideeducation.field_of_studyAlanineMental DisordersParkinson DiseaseMiddle AgedMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide; Aged; Aged 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Outcome Assessment Health CareEuropeSettore MED/26 - NEUROLOGIAFemaleErratumCohort studymedicine.medical_specialtyMonoamine Oxidase InhibitorsDrug-Related Side Effects and Adverse ReactionsPopulationMEDLINE03 medical and health sciencesCellular and Molecular NeuroscienceSafinamideInternal medicinemedicineHumansAdverse effecteducationAgedRetrospective Studiesbusiness.industryMAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamidemedicine.diseaseHealth Care030104 developmental biologychemistryParkinson’s diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of Parkinson's Disease
researchProduct

Prevalence of fatigue in Parkinson disease and its clinical correlates

2014

Objective: To assess in a noninterventional setting the prevalence and severity of fatigue in patients with Parkinson disease (PD). Methods: This was a cross-sectional study conducted in Italian patients with PD. Objectives included the evaluation of the current prevalence and severity of fatigue in patients with PD measured using the 16-item Parkinson Fatigue Scale (PFS-16), distressing fatigue (defined as a PFS-16 mean score $3.3), and assessment of its clinical correlates. Results: A total of 402 patients were enrolled and 394 patients completed the PFS-16 questionnaire with a PFS-16 mean (6SD) score of 2.87 6 0.99. Of these, 136 patients (33.8%) reported distressing fatigue (PFS-16 mean…

MaleTime FactorsDiseaseDSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th edition; ICD-10 5 International Classification of Diseases 10th revision; MAO-B 5 monoamine oxidase B; MS 5 multiple sclerosis; PD 5 Parkinson disease; PDQ-39 5 39-item Parkinson’s Disease Questionnaire; PDSS 5 Parkinson’s Disease Sleep Scale; PFS-16 5 16-item Parkinson Fatigue Scale; UPDRS 5 Unified Parkinson’s Disease Rating ScaleSeverity of Illness IndexQuality of life80 and overPrevalencePDSS 5 Parkinson’s Disease Sleep ScaleAge FactorDepression (differential diagnoses)FatigueAged 80 and overDepressionmusculoskeletal neural and ocular physiologyAge FactorsParkinson DiseasePDQ-39 5 39-item Parkinson’s Disease QuestionnaireMiddle AgedItalyPFS-16 5 16-item Parkinson Fatigue ScaleFemaleSettore MED/26 - NeurologiaMS 5 multiple sclerosiPsychologyHumanAdultSleep Wake Disordersmedicine.medical_specialtyPD 5 Parkinson diseasemacromolecular substancesArts and Humanities (miscellaneous)Internal medicinemedicineDistressingHumansIn patientAgedCross-Sectional StudieMAO-B 5 monoamine oxidase BUPDRS 5 Unified Parkinson’s Disease Rating Scalenervous system diseasesAdult; Age Factors; Aged; Aged 80 and over; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Neurology (clinical); Arts and Humanities (miscellaneous)Cross-Sectional Studiesnervous systemICD-10 5 International Classification of Diseases 10th revisionPhysical therapyNeurology (clinical)DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th editionSleep Disorder
researchProduct